Viokace FDA Approval History
Viokace (pancrelipase) is a combination of porcine-derived lipases, proteases, and amylases. Viokace, in combination with a proton pump inhibitor, is indicated in adults for the treatment of exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatectomy.
Development Timeline for Viokace
|Mar 1, 2012||Approval Aptalis Pharma Announces FDA Approval of Viokace (Pancrelipase) Tablets|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.